Analysis of bronchoalveolar lavage fluid in patients with chronic hepatitis C before and after treatment with interferon alpha

Thorax

Volumn 52, Issue 1, 1997, Pages 33-37

  Yamaguchi, Shinji ^a   Kubo, Keishi ^a   Fujimoto, Keisaku ^a   Honda, Takayuki ^a   Sekiguchi, Morie ^a   Sodeyama, Takeshi ^a  

^a SHINSHU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

alveolitis; chronic hepatitis C; interferon ; T cell subsets

Indexed keywords

ALPHA INTERFERON; CYTOKINE;

ADULT; ARTICLE; CHRONIC HEPATITIS; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATITIS C; HUMAN; LUNG ALVEOLITIS; LUNG DISEASE; LUNG FIBROSIS; LUNG FUNCTION TEST; LUNG LAVAGE; MALE; NEUTROPHIL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 0031022062     PISSN: 00406376     EISSN: None     Source Type: Journal    
DOI: 10.1136/thx.52.1.33     Document Type: Article

References (30)

1. O'Shea PA, Yardley JH. The Hamman-Rich syndrome in infancy: report of a case with virus-like particles by electron microscopy. Johns Hopkins Med J 1970;126:326-6.
2. Kawai T, Fujiwara T, Aoyama Y, Aizawa Y, Yamada Y, Aoyagi T, et al. Diffuse interstitial fibrosing pneumonitis and adenovirus infection. Chest 1976;69:692-4.
3. Geist LJ, Hunninhake GW. Potential role of viruses in the pathogenesis of pulmonary fibrosis. Chest 1993;103: 119-20S.
4. Crystal RG, Bitterman PB, Rennard SI, Hance AJ, Keogh BA. Interstitial lung disease of unknown cause. Disorders characterized by chronic inflammation of the lower respiratory tract. (First of two parts). N Engl J Med 1984; 310:154-66.
5. Choo Q-L, Kuo G, Weiner AJ, Overvy LR, Bradley DW, Houghton M. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science 1989;244:359-62.
6. Giusti G, Pasquale G, Galante D, Russo M, Sardaro C, Gallo C, et al. Clinical and histological aspects of chronic HCV infection and cirrhosis. Hepato-Gastroenterol 1993; 40:365-9.
7. Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi T, et al. Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. Am Rev Respir Dis 1992;146:266-8.
8. Meliconi R, Andreone P, Fasano L, Galli S, Pacilli A, Miniero R, et al. Incidence of hepatitis C virus infection in Italian patients with idiopathic pulmonary fibrosis. Thorax 1996;51:315-7.
9. Irving WL, Day S, Johnston IDA. Idiopathic pulmonary fibrosis and hepatitis C virus infection. Am Rev Respir Dis 1993;148:1683-4.
10. Kubo K, Yamaguchi S, Fujimoto K, Hanaoka M, Hayasaka M, Honda T, et al. Bronchoalveolar lavage fluid findings in patients with chronic hepatitis C virus infection. Thorax 1996;51:312-4.
11. Kamisako T, Adachi Y, Chihara J, Yamamoto T. Interstitial pneumonia and interferon-alpha. BMJ 1993;306:896.
12. Chin K, Tabata C, Satake N, Nagai S, Moriyama F, Kuno K. Pneumonitis associated with natural and recombinant interferon alpha therapy for chronic hepatitis C. Chest 1994;105:939-41.
13. Ogata K, Koga T, Yagawa K. Interferon-related bronchiolitis obliterans organizing pneumonia. Chest 1994;106:612-3.
14. Moriya K, Yasuda K, Koike K, Ichinose Y, Yatsuyanagi H, Kurokawa K, et al. Induction of interstitial pneumonitis during interferon treatment for chronic hepatitis C. J Gastroenterol 1994;29:514-7.
15. Burrows BB, Kasik JE, Niden AH, Barcley WR. Clinical usefulness of the single-breath pulmonary diffusion capacity test. Am Rev Respir Dis 1961;84:789-806.
16. Crystal RG, Reynolds HY, Kalica AR. Bronchoalveolar lavage. The report of an international conference. Chest 1986;90:122-31.
17. Reynolds HY. Bronchoalveolar lavage. Am Rev Respir Dis 1987;135:250-63.
18. The BAL Cooperative Group Steering Committee. Bronchoalveolar lavage constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison group. Am Rev Respir Dis 1990;141:S169-S202.
19. Mason PJ, Leslie CC, McCormick-Shannon K, Deterding RR, Nakamura T, Rubin JS, et al. Hepatocyte growth factor is a growth factor for rat alveolar type II cells. Am J Respir Cell Mol Biol 1994;11:561-7.
20. The BAL Cooperative Group Steering Committee. Bronchoalveolar constituents in healthy individuals, idiopathic pulmonary fibrosis, and selected comparison groups. Am Rev Respir Dis 1990;141:S169-96.
21. Laviolette M. Lymphocyte fluctuation in bronchoalveolar lavage fluid in normal volunteers. Thorax 1985;40:651-6.
22. Merchant RK, Schwartz DA, Helmers RA, Dayton CS, Hunninghake GW. Bronchoalveolar lavage cellularity. The distribution in normal volunteers. Am Rev Respir Dis 1992; 146:448-53.
23. Pestka S, Langer JA, Zoon KC, Samuel CE. Interferons and their actions. Ann Rev Biochem 1987;56:727-77.
24. Martin RJ, Boguniewicz M, Henson JE, Celniker AC, Williams M, Giorno RC, et al. The effects of inhaled interferon gamma in normal human airways. Am Rev Respir Dis 1993;148:1677-82.
25. Venge P, Dahl R, Hällgren R, Olsson I. Cationic proteins from human eosinophils and their role in the inflammatory reaction. In: Mahmoud AF, Austen AF, eds. Immunobiology of the eosinophil in health and disease. New York: Grune and Stratton, 1980:131-46.
26. Gleich GJ, Adolphson CR. The eosinophil leukocytes: structure and function. Adv Immunol 1986;39:177-253.
27. Ayars GH, Altman LC, Gleich G, Loegering DA, Baker CB. Eosinophil and eosinophil granule-mediated pneumocyte injury. J Allergy Clin Immunol 1985;76:595-604.
28. Peterson MW, Monick M, Hunninghake GW. Prognostic role of eosinophils in pulmonary fibrosis. Chest 1987;92: 51-6.
29. Walder S, Wiernik PH. Clinical update on the role of fluorouracil and recombinant interferon alfa-2α in the treatment of colorectal carcinoma. Semin Oncol 1990; 17(Suppl 1):16-21.
30. Meyers CA, Scheibel RS, Forman AD. Persistent neurotoxicity of systemically administered interferon-alpha. Neurology 1992;146:266-8.